Amanote Research
Register
Sign In
Erratum: The Efficacy and Safety of Anti‐PD‐1/Pd‐l1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First‐line Treatment for Advanced Lung Cancer
International Journal of Cancer
- United States
doi 10.1002/ijc.31820
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
December 7, 2018
Authors
Bo Zhang
Qiong Wu
Publisher
Wiley
Related search
The Efficacy and Safety of Anti-Pd-1/Pd-L1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First-Line Treatment for Advanced Lung Cancer
International Journal of Cancer
Cancer Research
Oncology
Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer
Journal of Cancer
Oncology
Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment
International Journal of Clinical Oncology
Medicine
Surgery
Oncology
Hematology
Anti-Pd-1/Pd-L1 Antibody Versus Conventional Chemotherapy for Previously-Treated, Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Journal of Thoracic Disease
Pulmonary
Respiratory Medicine
Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice
Cancer immunology research
Cancer Research
Immunology
P013 Anti-Pd-1 Combination Therapy as Second Line Treatment or Beyond in Patients With Advanced Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Real-World Evidenceand Clinical Observations of the Treatment of Advanced Non-Small Cell Lung Cancer With PD-1/PD-L1 Inhibitors
Scientific Reports
Multidisciplinary
PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer
Medicinski podmladak
Prostate Cancer Responds to Anti–PD-1–ctla4 Combo
Cancer Discovery
Oncology
